Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 Regimen Finding in Psoriasis
NCT00941031Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of secukinumab in plaque psoriasis (4 arms), sponsored by Novartis. Primary endpoint: Psoriasis Area and Severity Index 75 Response at 12 weeks. Started Jul 2009; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00941031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941031.